Understanding Peptide Bioavailability: Routes, Barriers, and Absorption Science

What Is Bioavailability?

Bioavailability (often abbreviated as “F”) is the fraction of an administered dose that reaches systemic circulation in its active, unchanged form. It is expressed as a percentage: intravenous administration has 100% bioavailability by definition (the entire dose enters the bloodstream), while other routes have lower bioavailability due to various absorption barriers and degradation processes.

For peptide research, bioavailability is a critical parameter because peptides face formidable biological barriers that small-molecule drugs do not. Understanding these barriers — and the strategies developed to overcome them — is essential for designing meaningful research protocols and interpreting experimental results.

The Bioavailability Equation

A peptide’s bioavailability through any non-intravenous route is determined by three sequential factors:

F = f_a × f_g × f_h

Where:

f_a = fraction absorbed across the biological membrane (epithelial barrier)
f_g = fraction surviving gut wall metabolism (for oral route) or local tissue metabolism
f_h = fraction surviving first-pass hepatic metabolism

For subcutaneous injection (the most common peptide route), f_g is essentially 1 (bypasses the gut) and f_h is variable depending on the peptide’s susceptibility to hepatic extraction.

Routes of Administration: A Bioavailability Comparison

Route	Typical Peptide Bioavailability	Key Barrier	Onset	Example
Intravenous (IV)	100% (by definition)	None	Immediate	Clinical settings
Subcutaneous (SC)	50-100%	Tissue proteases, lymphatic drainage	15-60 min	Most research peptides
Intramuscular (IM)	60-100%	Tissue proteases	10-30 min	IGF-1 LR3
Intranasal (IN)	1-30%	Mucociliary clearance, enzymatic barrier	5-15 min	Selank, Semax
Oral	0.1-2% (usually)	Gastric acid, proteases, epithelial barrier, first-pass	30-120 min	Oral semaglutide
Topical/Transdermal	<1-5%	Stratum corneum (skin barrier)	Variable	GHK-Cu (skin-local)
Sublingual	1-10%	Mucosal permeability, swallowing	10-30 min	Limited peptide data

Subcutaneous Injection: The Default Peptide Route

Subcutaneous (SC) injection is the most widely used route for peptide research because it provides:

High bioavailability (typically 50-90% for most peptides)
Slow, sustained absorption via capillary and lymphatic uptake
Avoidance of GI degradation and hepatic first-pass metabolism
Simple, reproducible technique with minimal equipment

How SC Absorption Works

After SC injection, the peptide encounters the subcutaneous tissue — a loose connective tissue layer between the dermis and muscle fascia, rich in adipocytes, fibroblasts, capillaries, and lymphatic vessels.

Absorption occurs via two pathways:

Capillary absorption (predominant for peptides <16 kDa): The peptide diffuses through the interstitial space and enters fenestrated capillaries. Absorption rate depends on molecular weight, charge, and local blood flow.
Lymphatic absorption (significant for peptides >16 kDa): Larger molecules enter the lymphatic system through gaps between lymphatic endothelial cells. Lymphatic drainage is slower than capillary absorption, producing a delayed and prolonged absorption profile.

Factors Affecting SC Bioavailability

Injection volume: Larger volumes create a larger depot that absorbs more slowly
Injection site: Abdomen > thigh > arm for absorption rate (due to differences in blood flow and subcutaneous tissue thickness)
Concentration: Very high concentrations may precipitate at the injection site, reducing bioavailability
Local proteases: Tissue proteases (cathepsins, matrix metalloproteinases) can degrade peptides before absorption

The Oral Bioavailability Challenge

Oral delivery is the most convenient route but the most challenging for peptides. The barriers are formidable and sequential:

Barrier 1: Gastric Acid and Pepsin

The stomach maintains a pH of 1.5-3.5 and contains pepsin — a protease with broad specificity. Most unprotected peptides are rapidly degraded in the gastric environment. Strategies to survive this barrier include enteric coating (protects until pH >5.5 in the duodenum) and co-administration with acid-neutralizing agents.

Barrier 2: Pancreatic Proteases

The duodenum receives pancreatic juice containing trypsin, chymotrypsin, elastase, and carboxypeptidases — an aggressive cocktail that rapidly hydrolyzes peptide bonds. This is the most significant enzymatic barrier for oral peptides.

Barrier 3: The Intestinal Epithelium

Even if a peptide survives enzymatic degradation, it must cross the intestinal epithelial barrier — a single layer of columnar epithelial cells connected by tight junctions. Peptides can cross via:

Transcellular transport: Passive diffusion through the cell membrane (favors small, lipophilic, uncharged molecules — the opposite of most peptides)
Paracellular transport: Through the spaces between cells (tight junctions normally block molecules >~500 Da)
Receptor-mediated transcytosis: Via specific receptors (limited to peptides that have evolved to use this pathway, such as insulin-like peptides)

Barrier 4: First-Pass Metabolism

Peptides absorbed from the GI tract enter the portal vein and pass through the liver before reaching systemic circulation. Hepatic proteases and metabolic enzymes further reduce bioavailability.

Intranasal Delivery: Bypassing the Blood-Brain Barrier

Intranasal administration is particularly relevant for neuropeptides (Selank, Semax, DSIP) because it provides a unique pathway to the central nervous system that bypasses the blood-brain barrier entirely.

The Nose-to-Brain Pathway

The nasal cavity contains the olfactory epithelium (upper nasal region) and is innervated by the olfactory nerve (CN I) and trigeminal nerve (CN V). Peptides applied intranasally can reach the brain via:

Olfactory pathway: Peptide absorbed by olfactory neurons travels along axons to the olfactory bulb, then distributes to the hippocampus, cortex, and other brain regions
Trigeminal pathway: Peptide absorbed along trigeminal nerve endings travels to the brainstem and distributes to wider CNS regions
Systemic absorption: Some peptide is absorbed into the nasal vasculature and enters systemic circulation (must then cross the BBB to reach the brain — less efficient for CNS delivery)

Intranasal Bioavailability Factors

Molecular weight: Smaller peptides (<1000 Da) generally have better nasal absorption
Mucociliary clearance: The nasal mucosa continuously clears foreign material toward the nasopharynx. Rapid clearance reduces contact time and absorption.
Enzymatic degradation: The nasal epithelium contains aminopeptidases, carboxypeptidases, and other proteases
Formulation: Mucoadhesive excipients, absorption enhancers, and viscosity modifiers can improve nasal retention and absorption

Topical and Transdermal Delivery

For skin-targeted peptides like GHK-Cu, topical application is relevant because the target tissue (dermis) is directly accessible:

The Skin Barrier

The stratum corneum (outermost skin layer) is the primary barrier to topical drug delivery. It consists of 15-20 layers of flattened, dead keratinocytes (corneocytes) embedded in a lipid matrix — often described as a “brick and mortar” structure. This barrier limits penetration to molecules that are:

Small (<500 Da — the “500 Dalton rule”)
Moderately lipophilic (log P of 1-3)
Uncharged

Most peptides violate all three criteria, making transdermal delivery inherently challenging.

Overcoming the Skin Barrier

Strategies for improving topical peptide delivery:

Chemical enhancers: Solvents (ethanol, propylene glycol), surfactants, and fatty acids that disrupt the stratum corneum lipid matrix
Physical methods: Microneedling creates temporary channels through the stratum corneum, dramatically increasing peptide penetration
Liposomal encapsulation: Peptides packaged in lipid vesicles (liposomes) can fuse with the stratum corneum lipids and release their contents into deeper skin layers
Copper peptides (GHK-Cu): Benefit from the relatively small size of the tripeptide (molecular weight ~404 Da for GHK alone), near the 500 Da threshold for skin penetration

Bioavailability Enhancement Strategies

Chemical Modifications

Modifications that improve bioavailability by resisting degradation:

Modification	Mechanism	Example
D-amino acid substitution	Resists proteases (stereospecific)	Semaglutide (Aib at position 2)
Cyclization	Blocks exopeptidases, constrains conformation	Cyclosporine (oral bioavailability ~30%)
PEGylation	Steric shielding from proteases, reduced renal clearance	PEG-interferon
Lipidation	Albumin binding extends half-life	Semaglutide (C18 fatty diacid)
N/C-terminal capping	Blocks aminopeptidases/carboxypeptidases	SNAP-8 (acetylated N-terminus)

Formulation Strategies

Approaches that improve absorption without modifying the peptide itself:

Absorption enhancers: Molecules that transiently increase membrane permeability (SNAC for oral semaglutide, chitosan for nasal delivery)
Protease inhibitors: Co-administered enzyme inhibitors (aprotinin, bestatin) that reduce local peptide degradation
Mucoadhesive formulations: Polymers that increase contact time with mucosal surfaces (intranasal, sublingual, buccal)
Nanoparticle encapsulation: Peptides packaged in polymer or lipid nanoparticles that protect from degradation and enhance uptake
Enteric coating: pH-sensitive coatings that protect oral peptides from gastric acid and release them in the intestine

Measuring Bioavailability in Research

Pharmacokinetic Studies

The gold standard for bioavailability determination is a crossover pharmacokinetic (PK) study:

Reference: Administer the peptide IV (100% bioavailability)
Test: Administer the same dose via the test route (SC, oral, intranasal, etc.)
Sample: Collect blood at multiple timepoints and measure peptide concentration
Calculate: Plot concentration vs. time curves and calculate area under the curve (AUC)

Bioavailability (F) = AUC_test / AUC_IV × 100%

Key PK Parameters

Parameter	Definition	Significance
C_max	Maximum plasma concentration	Relates to peak effect intensity
T_max	Time to reach C_max	Relates to onset of action
AUC	Area under the concentration-time curve	Relates to total drug exposure
t_1/2	Elimination half-life	Relates to duration of action and dosing frequency
F	Bioavailability	Fraction of dose reaching systemic circulation

Frequently Asked Questions

Why don’t all peptides just use IV administration for 100% bioavailability?

IV administration requires venous access (typically an IV line), carries infection risk, is inconvenient for repeated dosing, and produces a rapid bolus effect (high peak, rapid decline) rather than the sustained absorption profile that SC injection provides. For research and clinical use, SC injection is preferred for most peptides because it is simpler, safer, and provides a more pharmacokinetically favorable absorption profile.

Is oral BPC-157 effective despite low oral bioavailability?

BPC-157 is unusual in that it appears to exert local effects in the GI tract after oral administration — independent of systemic bioavailability. Research suggests that BPC-157 interacts with the GI mucosal surface and the enteric nervous system (the “gut-brain axis”) directly, which may not require high systemic absorption. This local GI activity distinguishes BPC-157 from most peptides, where systemic bioavailability is the relevant measure.

What determines whether a peptide can cross the blood-brain barrier?

The BBB allows passage of molecules that are small (<500 Da), lipophilic, and uncharged — properties that most peptides lack. Exceptions include peptides with specific transporter-mediated uptake (e.g., certain opioid peptides), lipophilic modified peptides (Dihexa), and peptides administered intranasally (which bypass the BBB entirely via the olfactory and trigeminal nerve pathways).

Does injection site matter for SC peptide bioavailability?

Yes. Subcutaneous tissue thickness, blood flow, and lymphatic drainage vary by anatomical site. The abdomen generally provides the fastest absorption, followed by the thigh and upper arm. Injection into areas with significant subcutaneous fat may slow absorption. Rotating injection sites is recommended to prevent local tissue reactions.

How does peptide molecular weight affect bioavailability?

Molecular weight influences bioavailability through multiple mechanisms: smaller peptides (<500 Da) may cross membranes more easily; peptides below ~60 kDa are rapidly cleared by the kidneys; and very large peptides (proteins >16 kDa) are absorbed primarily via the slower lymphatic route after SC injection. There is no single optimal size — the ideal molecular weight depends on the desired pharmacokinetic profile and administration route.

References

Fosgerau K, Hoffmann T. “Peptide therapeutics: current status and future directions.” Drug Discov Today. 2015;20(1):122-128.
Drucker DJ. “Advances in oral peptide therapeutics.” Nat Rev Drug Discov. 2020;19(4):277-289.
Renukuntla J, et al. “Approaches for enhancing oral bioavailability of peptides and proteins.” Int J Pharm. 2013;447(1-2):75-93.
Lochhead JJ, Thorne RG. “Intranasal delivery of biologics to the central nervous system.” Adv Drug Deliv Rev. 2012;64(7):614-628.
Banga AK. “Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems.” CRC Press. 3rd ed. 2015.
Buckley ST, et al. “Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.” Sci Transl Med. 2018;10(467):eaar7047.
Anselmo AC, et al. “Non-invasive delivery strategies for biologics.” Nat Rev Drug Discov. 2019;18(1):19-40.
Deng F, Bhatt S. “Dermal absorption of peptides.” Expert Opin Drug Deliv. 2020;17(11):1547-1560.